{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:09:01Z","timestamp":1749182941234,"version":"3.41.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate trends and the potential impact of the COVID-19 pandemic on the utilization of intravitreal antivascular endothelial growth factor (anti-VEGF) pharmaceuticals in an accountable care organization (ACO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively analyzed the Centers for Medicare and Medicaid Services beneficiary claims for all patients in the Houston Methodist Coordinated Care ACO registry during the years 2018, 2019, and 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Across the 3 years studied, a mean of 708 patients received anti-VEGF injections per year. The percentage of patients who received anti-VEGF injections decreased in each sequential year, with a steeper decline during the COVID-19 pandemic in the year 2020 (decrease by 0.4% from 2019 to 2020, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001; decrease by 0.2% from 2018 to 2019, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.1453). The percentage of patients receiving bevacizumab of the total number of patients receiving any anti-VEGF treatment decreased (bevacizumab decreased by 6% from 2019 to 2020, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0174; decreased by 7% from 2018 to 2019, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0074). The COVID-19 pandemic did not seem to correlate with a change in the distribution of the specific anti-VEGF injection used.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Despite the lower price which may correlate with value-based care, bevacizumab was the least used anti-VEGF treatment. COVID-19 correlated with a larger decrease in the utilization of all three anti-VEGF drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003679","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T22:09:47Z","timestamp":1675375787000},"page":"506-513","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM"],"prefix":"10.1097","volume":"43","author":[{"given":"Cyrus","family":"Daruwalla","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Andrieni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Houston Methodist Hospital, Houston, Texas;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York City, New York;"},{"name":"Department of Medicine, Texas A&M School of Medicine, College Station Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enshuo","family":"Hsu","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research, Houston Methodist Hospital, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Uzair","sequence":"additional","affiliation":[{"name":"Houston Methodist Coordinated Care ACO, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas;"},{"name":"Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"},{"name":"Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas;"},{"name":"Ophthalmology, Weill Cornell Medicine, New York City, New York;"},{"name":"Department of Ophthalmology, University of Texas Medical Branch, Galveston, Texas;"},{"name":"Department of Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Glassman","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic Retinopathy clinical research Network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration","volume":"218","author":"Brown","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R7-20250605","first-page":"253","article-title":"Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema","volume":"26","author":"Kiss","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/OPTH.S296345","article-title":"Short-term effects of COVID-19-related deferral of intravitreal injection visits","volume":"15","author":"Ashkenazy","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","article-title":"How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview","volume":"36","author":"Empeslidis","year":"2019","journal-title":"Adv Ther"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"R15-20250605","first-page":"CD007419","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","volume":"12","author":"Virgili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ICU.0b013e32835f8ec0","article-title":"Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration","volume":"24","author":"Johnson","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:06:56Z","timestamp":1749143216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003679","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}